AOD-9604 for Weight Loss: What the Evidence Shows
What human and animal studies show about AOD-9604 for weight loss, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Animal
- Human studies
- None found
- with an outcome for weight loss, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- 3
- with an outcome for weight loss, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 3
- with an outcome for weight loss
Evidence for weight loss
Each row is an outcome related to weight loss from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Body weight gain and fat oxidation | Both hGH and AOD reduced weight gain in obese mice, with higher fat oxidation and plasma glycerol. | Animal · mouse (not a human result) | International journal of obesity and related metabolic disorders 2001, PMID 11673763 |
| Glucose effects | AOD9604 did not cause hyperglycaemia or reduce insulin secretion, unlike hGH. | Animal · mouse (not a human result) | International journal of obesity and related metabolic disorders 2001, PMID 11673763 |
| Body weight and fat | Both reduced body weight and body fat in obese mice over 14 days. | Animal · mouse (not a human result) | Endocrinology 2001, PMID 11713213 |
| Knock-out mice | In beta(3)-AR knock-out mice long-term treatment did not change body weight as in wild-type. | Animal · mouse (not a human result) | Endocrinology 2001, PMID 11713213 |
| Body weight gain | Oral AOD9604 for 19 days cut body weight gain by over 50% (15.8 g vs 35.6 g control) in obese Zucker rats. | Animal · rat (not a human result) | Hormone research 2000, PMID 11146367 |
| Insulin sensitivity | No adverse effect on insulin sensitivity, unlike intact hGH. | Animal · rat (not a human result) | Hormone research 2000, PMID 11146367 |
AOD-9604 and weight loss are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Animal data: rats and mice only
In obese Zucker rats, 19 days of an oral AOD9604 dose of 500 microg/kg reduced body weight gain by over 50% compared with controls.[3]
In obese mice, AOD9604 and growth hormone both reduced weight gain, with increased fat oxidation and raised plasma glycerol (an index of lipolysis).[1]
In mice lacking the beta-3 adrenergic receptor, long-term AOD9604 did not change body weight or lipolysis as it did in wild-type mice.[2]
Human evidence and anti-doping status
WADA's prohibited list names AOD-9604 as an example of a banned growth hormone fragment.[4]
Other peptides people research for weight loss
All peptides for weight loss, comparedCommon questions
Does AOD-9604 help with weight loss?
The strongest study we summarise for weight loss is animal evidence, across 3 studies with an outcome for weight loss. That is not proof it works in people.
Is AOD-9604 approved for weight loss?
No. AOD-9604 is not FDA approved for any use, including weight loss.
What is the best peptide for weight loss?
There is no single answer. Our weight loss overview compares each candidate by evidence grade and legal status rather than by popularity.
Does AOD-9604 work for fat loss?
In rats and mice it reduced body weight gain. The cached abstracts report no human efficacy result.[3]
Is AOD-9604 banned in sport?
Yes: the WADA list names AOD-9604 as an example of a banned growth hormone fragment.[4]
Is AOD-9604 the same as growth hormone?
It is a fragment: the C-terminal amino acids 177-191 of human growth hormone, with an extra tyrosine at the N-terminus.[5]
More on AOD-9604
Sources
- 1Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
- 2The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.Endocrinology · 2001PMID 11713213Accessed 2 Oct 2026
- 3Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026 (in effect 1 January 2026)World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 11 Oct 2026
Found an error? Report a correction.